Shanghai Hepu Pharmaceutical Co., Ltd. is located in the National Biomedical Industry Base of Zhangjiang Hi-Tech Park in Shanghai, with a registered capital of 77.5 million yuan. It is the first batch of key start-up enterprises in Shanghai Pudong New Area. The company focuses on the research and development of original new drugs, and has the overall R & D capabilities from new drug conceptual design, preclinical research, pilot test research to clinical research and mass production of new drugs. He is currently researching and developing Hepatitis B including Hepatide, diabetes, non-alcoholic fatty liver disease, and hyperlipidemia.
Undertook the "Major New Drug Creation" National Science and Technology Major Project "Research on Hepatite, a New Drug for Hepatitis B Virus Entry Blocking Strategy" (Project Number: 2011ZX09102-009-08); Medicine) Phase III Clinical Research "(Project ID: 2017ZX09309004).
Current hepatitis B drugs only exert an inhibitory effect on HBV in infected hepatocytes and cannot protect healthy hepatocytes from HBV reinfection. Hepalin developed by Hepu Pharmaceutical can block HBV infection of hepatocytes, interrupt the virus removal in the current treatment of hepatitis B → reinfect the long cycle, improve the treatment efficiency of chronic hepatitis B, and may make chronic hepatitis B complete. cure.
Diabetes is a systemic disease of glucose and lipid metabolism. Existing drugs have not yet been able to target multiple metabolic pathways, and need to take a variety of different drugs to achieve therapeutic purposes. Globally, Hepalatide uses NTCP as the target for diabetes treatment for the first time, comprehensively controls blood sugar, blood lipids and cholesterol, and effectively protects the liver and pancreatic islets. Improve patients' metabolic function.
The Chinese patent application for the pharmaceutical infrastructure was filed on August 12, 2005 (CN200510028721) and has been authorized. After 5 years of development and transformation, Hepalatide submitted a Chinese patent application for an optimized structure that completely covers the current drug on May 14, 2010, and has been authorized (CN201010174788). The patent application filed a PCT application (PCT / CN2011 / 073963) on May 12, 2011, and has entered countries with high incidence of hepatitis B and large populations in India and Indonesia.
The Chinese invention patent of the hepalatide preparation was applied on July 1, 2013, and the corresponding PCT international patent application was filed. , Europe, United States.
After the verification of the effect of hepalatide on diabetes treatment, the application patent of hepalatide for the treatment of metabolic diseases including diabetes was submitted on May 30, 2016, and the corresponding PCT patent is planned to enter the United States and Europe And Japan.
The founder of the company, Dr. Liu Hongli, graduated from the Department of Clinical Medicine of the Third Military Medical University. He has served as a surgeon, director of the medical department of Shanghai Biotechnology Co., Ltd., and assistant to the president. He received a doctorate in immunology from the Third Military Medical University. Has rich experience in clinical practice, basic research and development, clinical research and company management. He is good at the research and development of new drugs, and presided over the design and implementation of several new class I new drugs in preclinical research and clinical research (class I biological new drugs oncolytic virus-Ankerui, tumor immunotherapy-H103 VS T-VEC, etc.). Since 2008, he has presided over the preclinical research and development of Hepalatide. In 2010, he founded Shanghai Hepu Biotechnology Co., Ltd. He is the inventor of Hepalatide and the person in charge of a major national science and technology project.
The company's core team has the full process of research and development of new drugs from structural discovery, clinical research to the launch of new drugs.